Do You Always Follow Clinical Guidelines?

December 04, 2019

In 2017, oncologist Talal Hilal, MD, treated a patient who had hepatocellular cancer that was progressing despite the best available therapies. A recently updated and influential guideline for cancer care offered an additional option: nivolumab, an immune checkpoint inhibitor.

Hilal offered the patient the new drug, but it didn't work. The patient died soon after, and later a large study failed to show that nivolumab improved outcomes for patients with hepatocellular cancer in the front-line setting.

"Guidelines convey a false sense of certainty," Hilal wrote in a Medscape perspective article. "In science, there is no absolute certainty. Today's best practice may be abandoned tomorrow. Guidelines that propagate treatments without acknowledging their uncertainty can be harmful."


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: